Background: Intracranial germinomas (IG) are rare and highly curable tumors. The incidence and optimal treatment of recurrences are not well defined. Case Report: A 34-year-old male was diagnosed with a late recurrence of an IG 14 years after the initial diagnosis and treatment. The diagnosis was complicated by the absence of tumor markers and delayed histological sampling of the lesion. Upon histological confirmation, the patient received 2 cycles of conventional chemotherapy, followed by 2 cycles of highdose chemotherapy and peripheral blood stem cell transplantation. The patient achieved a complete remission on magnetic resonance imaging scan. Consolidating radiation of the involved field was performed after termination of the chemotherapy. Conclusion: Limited information on the optimal management of late relapses of IG call for individualized therapeutic approaches. Platinum-based chemotherapy, followed by high-dose chemotherapy and consolidative radiation, appears to be feasible and effective in this situation.

Keywords:
Intracranial germinoma, Late relapse, High-dose chemotherapy
1.
Aoyama H, Shirato H, Ikeda J, Fujieda K, Miyasaka K, Sawamura Y: Induction chemotherapy followed by low-dose involved-field radiotherapy for intracranial germ cell tumors. J Clin Oncol 2002;20:857-865.
2.
Nguyen QN, Chang EL, Allen PK, Maor MH, Ater JL, Mahajan A, Wolff JE, Weinberg JS, Woo SY: Focal and craniospinal irradiation for patients with intracranial germinoma and patterns of failure. Cancer 2006;107:2228-2236.
3.
Osuka S, Tsuboi K, Takano S, Ishikawa E, Matsushita A, Tokuuye K, Akine Y, Matsumura A: Long-term outcome of patients with intracranial germinoma. J Neurooncol 2007;83:71-79.
4.
Chao CK, Lee ST, Lin FJ, Tang SG, Leung WM: A multivariate analysis of prognostic factors in management of pineal tumor. Int J Radiat Oncol Biol Phys 1993;27:1185-1191.
5.
Tokoro K, Chiba Y, Murase S, Yagishita S, Kyuma Y: Subarachnoid dissemination of pineal germinoma 9 years after radiation therapy without local relapse - case report. Neurol Med Chir (Tokyo) 1991;31:725-728.
6.
Von Rohr E, Gonner F, Schroth G, Cerny T: Relapse and subarachnoid dissemination of a pineal germinoma 14 years after radiation therapy. J Clin Neurosci 1999;6:247-249.
7.
Bamberg M, Kortmann RD, Calaminus G, Becker G, Meisner C, Harms D, Gobel U: Radiation therapy for intracranial germinoma: results of the German cooperative prospective trials MAKEI 83/86/89. J Clin Oncol 1999;17:2585-2592.
8.
Alapetite C, Brisse H, Patte C, Raquin MA, Gaboriaud G, Carrie C, Habrand JL, Thiesse P, Cuilliere JC, Bernier V, Ben-Hassel M, Frappaz D, Baranzelli MC, Bouffet E: Pattern of relapse and outcome of non-metastatic germinoma patients treated with chemotherapy and limited field radiation: the SFOP experience. Neuro Oncol 2010; 12:1318-1325.
9.
Jennings MT, Gelman R, Hochberg F: Intracranial germ-cell tumors: natural history and pathogenesis. J Neurosurg 1985;63:155-167.
10.
Echevarria ME, Fangusaro J, Goldman S: Pediatric central nervous system germ cell tumors: a review. Oncologist 2008;13:690-699.
11.
Kaatsch P: Epidemiology of childhood cancer. Cancer Treat Rev 2010;36:277-285.
12.
Shim KW, Kim TG, Suh CO, Cho JH, Yoo CJ, Choi JU, Kim JH, Kim DS: Treatment failure in intracranial primary germinomas. Childs Nerv Syst 2007;23:1155-1161.
13.
Matsutani M: Pineal germ cell tumors. Prog Neurol Surg 2009;23:76-85.
14.
Jensen AW, Laack NN, Buckner JC, Schomberg PJ, Wetmore CJ, Brown PD: Long-term follow-up of dose-adapted and reduced-field radiotherapy with or without chemotherapy for central nervous system germinoma. Int J Radiat Oncol Biol Phys 2010; 77:1449-1456.
15.
Douglas JG, Rockhill JK, Olson JM, Ellenbogen RG, Geyer JR: Cisplatin-based chemotherapy followed by focal, reduced-dose irradiation for pediatric primary central nervous system germinomas. J Pediatr Hematol Oncol 2006;28:36-39.
16.
Khatua S, Dhall G, O'Neil S, Jubran R, Villablanca JG, Marachelian A, Nastia A, Lavey R, Olch AJ, Gonzalez I, Gilles F, Nelson M, Panigrahy A, McComb G, Krieger M, Fan J, Sposto R, Finlay JL: Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation. Pediatr Blood Cancer 2010;55:42-46.
17.
Kretschmar C, Kleinberg L, Greenberg M, Burger P, Holmes E, Wharam M: Pre-radiation chemotherapy with response-based radiation therapy in children with central nervous system germ cell tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer 2007;48:285-291.
18.
Allen JC, Kim JH, Packer RJ: Neoadjuvant chemotherapy for newly diagnosed germ-cell tumors of the central nervous system. J Neurosurg 1987;67:65-70.
19.
Yoshida J, Sugita K, Kobayashi T, Takakura K, Shitara N, Matsutani M, Tanaka R, Nagai H, Yamada H, Yamashita J, et al.: Prognosis of intracranial germ cell tumours: effectiveness of chemotherapy with cisplatin and etoposide (CDDP and VP-16). Acta Neurochir (Wien) 1993;120:111-117.
20.
Kumabe T, Kusaka Y, Jokura H, Ikeda H, Shirane R, Yoshimoto T: (Recurrence of intracranial germinoma initially treated with chemotherapy only). No Shinkei Geka 2002;30:935-942.
21.
Kellie SJ, Boyce H, Dunkel IJ, Diez B, Rosenblum M, Brualdi L, Finlay JL: Intensive cisplatin and cyclophosphamide-based chemotherapy without radiotherapy for intracranial germinomas: failure of a primary chemotherapy approach. Pediatr Blood Cancer 2004;43:126-133.
22.
Chen YW, Huang PI, Ho DM, Hu YW, Chang KP, Chiou SH, Guo WY, Chang FC, Liang ML, Lee YY, Chen HH, Hsu TR, Lin SC, Wong TT, Yen SH: Change in treatment strategy for intracranial germinoma: long-term follow-up experience at a single institute. Cancer 2012;15;118:2752-2762.
23.
Kamoshima Y, Sawamura Y, Ikeda J, Shirato H, Aoyama H: Late recurrence and salvage therapy of CNS germinomas. J Neurooncol 2008;90:205-211.
24.
Hu YW, Huang PI, Wong TT, Ho DM, Chang KP, Guo WY, Chang FC, Shiau CY, Liang ML, Lee YY, Chen HH, Yen SH, Chen YW: Salvage treatment for recurrent intracranial germinoma after reduced-volume radiotherapy: a single-institution experience and review of the literature. Int J Radiat Oncol Biol Phys 2012;84:639-647.
25.
Kadota RP, Mahoney DH, Doyle J, Duerst R, Friedman H, Holmes E, Kun L, Zhou T, Pollack IF: Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. Pediatr Blood Cancer 2008;51:675-678.
26.
Modak S, Gardner S, Dunkel IJ, Balmaceda C, Rosenblum MK, Miller DC, Halpern S, Finlay JL: Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors. J Clin Oncol 2004;22:1934-1943.
27.
Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U, Flechon A, Margolin K, Lotz JP, Germa-Lluch JR, Powles T, Kollmannsberger C, Beyer J: Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 2011;29:2178-2184.
28.
Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Flechon A, Margolin KA, Lotz JP, Germa Lluch JR, Powles T, Kollmannsberger CK: Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 2010;28:4906-4911.
© 2013 S. Karger GmbH, Freiburg
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.